We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Safety and Efficacy of Autologous Bone Marrow Stem Cells for Lower Extremity Ischemia Treating

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01903044
Recruitment Status : Active, not recruiting
First Posted : July 19, 2013
Last Update Posted : December 13, 2017
Information provided by (Responsible Party):

Study Description
Brief Summary:
The purpose of this study is to determine whether autologous bone marrow-derived stem cells are effective in the treatment of lower extremity ischemia.

Condition or disease Intervention/treatment Phase
Lower Extremity Ischemia Leg Ulcer Peripheral Vascular Disease Diabetic Foot Gangrene Procedure: BM-MNC injection Phase 1 Phase 2

Detailed Description:
Critical limb ischemia (CLI) is a debilitating and disabling disease. Symptoms include pain at rest, loss of tissue integrity, distal amputations and have a major impact on the quality of life. Despite recent advances in surgical vascular procedures, a large number of patients (approximately 40%) are not eligible for these revascularization procedures. New strategies for revascularization need to be explored. Besides, in some cases results of such interventions do not give desirable effect, search of new methods of treatment therefore is necessary. Recent evidence indicates that bone marrow-derived mononuclear cells (BM-MNC) are a potential new therapeutic target.

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Multicentric Study of the Autologous Bone Marrow-derived Mononuclear Cells Injection for Treatment of the Patients With Critical Lower Extremity Ischemia
Study Start Date : September 2014
Primary Completion Date : March 2017
Estimated Study Completion Date : September 2018
Arms and Interventions

Arm Intervention/treatment
Experimental: BM-MNC injection
Injection of autologous bone marrow-derived mononuclear cells
Procedure: BM-MNC injection
BM-MNC cells will be injected in aliquots of 1 ml at multiple regions of the leg muscles

Outcome Measures

Primary Outcome Measures :
  1. Wound healing (wound size, wound stage) - monitoring the healing of trophic lesions [ Time Frame: 3 months ]

Secondary Outcome Measures :
  1. Clinical outcome classification [ Time Frame: 3 months, 6 months ]
    Improvement of symptoms, functional capacity, exercises tolerance assessed by change in Rutherford scale of CLI

  2. Pain and analgesics use [ Time Frame: 3 months ]
  3. Quality of life outcome [ Time Frame: 3 months, 6 months ]
  4. Improvement of the coronary and collateral circulation. [ Time Frame: 3 months ]
  5. Survival without amputation [ Time Frame: 6 months ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Critical lower limb ischemia, defined as ischemic pain at rest and / or the presence of minor tissue loss, with the possibility of healing.
  • Failure of conventional medical treatment and attempts to open or percutaneous revascularization before, with an observation period of two months after the last attempt at revascularization.
  • Patients considered at high risk for new revascularization procedure by at least two independent observers.

Exclusion Criteria:

  • Expected life span less than six months
  • Large tissue loss in the ischemic limb indicating the need for limb amputation in the short term.
  • Evidence of osteomyelitis in the ischemic extremity.
  • Current or previous history of neoplasia.
  • Unstable angina, recent stroke or other medical condition that contraindicate anesthesia for bone marrow aspiration.
  • Proliferative retinopathy.
  • Debilitating disease with a life span less than one year.
  • Myelofibrosis, myelodysplasia or other diseases that affect the bone marrow.
  • Use of alcohol in excess of twice-daily doses or history of illicit drug use.
  • Need for continuous high doses of drug therapy with steroids (more than 7.5 mg/day).
  • Positivity for HIV or syphilis
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01903044

Pontifícia Universidade Católica do Paraná
Curitiba, Paraná, Brazil, 80215-901
Sponsors and Collaborators
Pontifícia Universidade Católica do Paraná
Instituto de Moléstias Cardiovasculares de São José do Rio Preto, Brazil
Hospital Sao Rafael
Hospital Geral Nacional Enrique Cabrera, Cuba
Instituto de Hematología e Inmunología, Cuba
Fundação Araucária
Principal Investigator: Paulo Brofman, PhD Pontifícia Universidade Católica do Paraná
More Information

Responsible Party: Alexandra Cristina Senegaglia, PhD, Pontifícia Universidade Católica do Paraná
ClinicalTrials.gov Identifier: NCT01903044     History of Changes
Other Study ID Numbers: ICMI_ 404732/2012-7
First Posted: July 19, 2013    Key Record Dates
Last Update Posted: December 13, 2017
Last Verified: December 2017

Keywords provided by Alexandra Cristina Senegaglia, Pontifícia Universidade Católica do Paraná:
Lowe extremity ischemia
Bone marrow

Additional relevant MeSH terms:
Diabetic Foot
Vascular Diseases
Leg Ulcer
Peripheral Vascular Diseases
Peripheral Arterial Disease
Pathologic Processes
Diabetic Angiopathies
Cardiovascular Diseases
Foot Ulcer
Skin Ulcer
Skin Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Diabetic Neuropathies
Arterial Occlusive Diseases